An Oncology biotech pioneering  RAD51 inhibition to treat high replication stress tumors

Author name: admin

Satya to present preclinical profile of its PARG inhibitors at the 2024 American Association for Cancer Research (AACR) Annual Meeting – April 5-10, San Diego, CA

Abstract title Preclinical profile of novel and potent small molecule inhibitors of PARG Poster number 7112 Session title DNA Damage and Repair                             Session date and time April 10, 9:00 AM – 12:30 PM Session category Experimental and Molecular therapeutics Abstract title: Preclinical profile of novel and potent small molecule inhibitors of PARG Abstract:Poly(ADP-ribose) glycohydrolase (PARG) is

Satya to present preclinical profile of its PARG inhibitors at the 2024 American Association for Cancer Research (AACR) Annual Meeting – April 5-10, San Diego, CA Read More »

Satya to present the preclinical profile of first-in-class RAD51 inhibitors at the Upcoming ESMO Congress – Oct 20-24, Madrid, Spain

  Abstract title SAT-122, a potential first-in-class, potent, small-molecule disruptor of RAD51-BRCA2, attenuates RAD51 foci formation and tumor progression in preclinical models Poster number FPN: 35P Publication category Basic science  Session date and time Sunday, October 22 | 9:00 am-5:00 pm Session location Hall 8 Abstract title: SAT-122, a potential first-in-class, potent, small-molecule disruptor of RAD51-BRCA2,

Satya to present the preclinical profile of first-in-class RAD51 inhibitors at the Upcoming ESMO Congress – Oct 20-24, Madrid, Spain Read More »

Satya to Highlight its SOS1 inhibitors that demonstrate best-in-class single agent activity in preclinical models of KRAS driven tumors at the Upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics – Oct 11-15, Boston, USA

  Abstract title Best in class, potent, SOS1 inhibitors demonstrate single agent activity in preclinical models of KRAS driven tumors Poster number A099 Session Poster Session A                              Session date and time Thursday, October 12 | 12:30 pm-4:00 pm Session location Level 2, Exhibit Hall D Abstract title: Best in class, potent, SOS1 inhibitors demonstrate single agent activity

Satya to Highlight its SOS1 inhibitors that demonstrate best-in-class single agent activity in preclinical models of KRAS driven tumors at the Upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics – Oct 11-15, Boston, USA Read More »

Satya to present preclinical profile of its KIF18A inhibitors at the Upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics – Oct 11-15, Boston, USA

  Abstract title Preclinical profile of novel and potent small molecule inhibitors of KIF18A inhibitors in chromosomally unstable solid tumor lines Poster number A024 Session Poster Session A                              Session date and time Thursday, October 12 | 12:30 pm-4:00 pm Session location Level 2, Exhibit Hall D Abstract title: Preclinical profile of novel and potent small molecule inhibitors

Satya to present preclinical profile of its KIF18A inhibitors at the Upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics – Oct 11-15, Boston, USA Read More »

Scroll to Top